ELVN
Price
$21.91
Change
+$2.25 (+11.44%)
Updated
Jun 13 closing price
Capitalization
1.08B
53 days until earnings call
ERAS
Price
$1.48
Change
-$0.05 (-3.27%)
Updated
Jun 13 closing price
Capitalization
419.27M
53 days until earnings call
Interact to see
Advertisement

ELVN vs ERAS

Header iconELVN vs ERAS Comparison
Open Charts ELVN vs ERASBanner chart's image
Enliven Therapeutics
Price$21.91
Change+$2.25 (+11.44%)
Volume$3.22M
Capitalization1.08B
Erasca
Price$1.48
Change-$0.05 (-3.27%)
Volume$1.46M
Capitalization419.27M
ELVN vs ERAS Comparison Chart
Loading...
ELVN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ELVN vs. ERAS commentary
Jun 15, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ELVN is a StrongBuy and ERAS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 15, 2025
Stock price -- (ELVN: $21.91 vs. ERAS: $1.48)
Brand notoriety: ELVN and ERAS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ELVN: 772% vs. ERAS: 99%
Market capitalization -- ELVN: $1.08B vs. ERAS: $419.27M
ELVN [@Biotechnology] is valued at $1.08B. ERAS’s [@Biotechnology] market capitalization is $419.27M. The market cap for tickers in the [@Biotechnology] industry ranges from $355.9B to $0. The average market capitalization across the [@Biotechnology] industry is $2.45B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ELVN’s FA Score shows that 0 FA rating(s) are green whileERAS’s FA Score has 1 green FA rating(s).

  • ELVN’s FA Score: 0 green, 5 red.
  • ERAS’s FA Score: 1 green, 4 red.
According to our system of comparison, ELVN is a better buy in the long-term than ERAS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ELVN’s TA Score shows that 6 TA indicator(s) are bullish while ERAS’s TA Score has 6 bullish TA indicator(s).

  • ELVN’s TA Score: 6 bullish, 4 bearish.
  • ERAS’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, both ELVN and ERAS are a good buy in the short-term.

Price Growth

ELVN (@Biotechnology) experienced а +5.64% price change this week, while ERAS (@Biotechnology) price change was -7.50% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.75%. For the same industry, the average monthly price growth was +12.94%, and the average quarterly price growth was +4.02%.

Reported Earning Dates

ELVN is expected to report earnings on Aug 07, 2025.

ERAS is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (-0.75% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ELVN($1.08B) has a higher market cap than ERAS($419M). ELVN YTD gains are higher at: -2.622 vs. ERAS (-41.036). ELVN has higher annual earnings (EBITDA): -104.24M vs. ERAS (-151.33M). ERAS (319M) and ELVN (313M) have equal amount of cash in the bank . ELVN has less debt than ERAS: ELVN (0) vs ERAS (52.9M). ELVN (0) and ERAS (0) have equivalent revenues.
ELVNERASELVN / ERAS
Capitalization1.08B419M257%
EBITDA-104.24M-151.33M69%
Gain YTD-2.622-41.0366%
P/E RatioN/AN/A-
Revenue00-
Total Cash313M319M98%
Total Debt052.9M-
TECHNICAL ANALYSIS
Technical Analysis
ELVNERAS
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
82%
MACD
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
77%
Advances
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 6 days ago
79%
Declines
ODDS (%)
Bearish Trend 6 days ago
90%
Bearish Trend 4 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
82%
Aroon
ODDS (%)
Bullish Trend 2 days ago
75%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ELVN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
QIBGX22.18-0.22
-0.98%
Federated Hermes MDT Balanced IS
OTCCX21.43-0.27
-1.24%
MFS Mid Cap Growth C
PTSGX17.15-0.25
-1.44%
Touchstone Sands Capital Select Growth Z
GSCYX16.81-0.29
-1.70%
GuideStone Funds Small Cap Equity Instl
MMEAX38.98-0.93
-2.33%
Victory Integrity Discovery A

ELVN and

Correlation & Price change

A.I.dvisor indicates that over the last year, ELVN has been loosely correlated with ERAS. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if ELVN jumps, then ERAS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ELVN
1D Price
Change %
ELVN100%
+11.44%
ERAS - ELVN
50%
Loosely correlated
-3.27%
DNLI - ELVN
49%
Loosely correlated
-2.51%
APGE - ELVN
49%
Loosely correlated
+6.26%
CRNX - ELVN
47%
Loosely correlated
-1.24%
COGT - ELVN
46%
Loosely correlated
-1.94%
More

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with RVMD. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then RVMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
-3.27%
RVMD - ERAS
57%
Loosely correlated
-1.26%
LRMR - ERAS
54%
Loosely correlated
-1.03%
XNCR - ERAS
54%
Loosely correlated
-2.55%
ATXS - ERAS
52%
Loosely correlated
+2.14%
IMNM - ERAS
52%
Loosely correlated
-6.03%
More